The International Contrast Ultrasound Society (ICUS)

Bracco's Lumason contrast agent approved by FDA

Bracco Diagnostics has received approval for its Lumason ultrasound contrast agent, which now joins Definity (Lantheus Medical Imaging) and Optison (GE Healthcare) as approved ultrasound contrast agents in the U.S. Known previously as SonoVue, Lumason (sulfur hexafluoride lipid microbubbles) is indicated for patients whose echocardiography images are hard to see with ultrasound, according to the FDA.

Click here for full FDA statement:

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:







ICUS Tweets

Detect liver cancer effectively and more cheaply, without harmful radiation imaging or costly MRI eqpt. Read more:
Lose weight while you sleep? Maybe soon! Read more at:
Follow Bubble Conference 2016 comment at #bubble2016

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News Bracco's Lumason contrast agent approved by FDA